Previously, pharmacogenetic studies have demonstrated that women with a certain genotype have a better response to tamoxifen. Now, a modeling study has shown that for postmenopausal breast cancer patients with this genotype, tamoxifen is as good or better at reducing the risk for relapse as aromatase inhibitors. This finding does have clinical implications, but routine [...]
Entries from April 30th, 2008
Breast cancer update: will genotyping help select best patients?
April 30th, 2008 · No Comments · breast cancer, competitive intelligence, market intelligence, market trends, oncology
Tags:
Market intelligence – when NICE is not so nice
April 29th, 2008 · No Comments · Roche, Tarceva, company news, competitive intelligence, market intelligence, market trends
The National Institute for Health and Clinical Excellence (NICE) have announced their decision not to recommend the use of Tarceva (erlotinib) for the treatment of locally-advanced or metastatic non-small-cell lung cancer (NSCLC) in the National Health Service (NHS) in England and Wales. NICE’s Final Appraisal Determination (FAD) on Tarceva last week concluded that the drug [...]
Tags:
New cancer therapy being market tested for gliobastoma?
April 28th, 2008 · No Comments · Gliobastoma, cancer, consulting, market intelligence, market trends, oncology
Glioblastoma multiforme is by far the most common and most malignant of the glial tumors, yet prognosis remains poor. Less than 5% of patients survive 5 years after diagnosis. Preliminary data was recently reported at a cancer conference on an investigational compound has shown promise in prolonging survival among patients with recurrent glioblastoma. This compound, [...]
Tags: